L-Arginine Cardiovascular Randomized Trial Evidence Table

Structured evidence table for L-Arginine Cardiovascular Randomized Trial, generated from 2 reusable source documents in the Migaku knowledge base.

topicclaimevidence levelcitationsource
L-Arginine Cardiovascular Randomized TrialMore importantly, this BP elevation was closely associated with adverse outcomes, with cardiovascular mortality risk increasing by 21% for every 10 mmHg increase in SBP, and winter cardiovascular mortality rates being 41% higher than those in summer (Yang et al. ).1Luo Ping (2026)Effect of L‐Citrulline Intake on Blood Pressure in Cold Environments: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
L-Arginine Cardiovascular Randomized TrialGiven that cold environment‐induced BP elevation is one of the important modifiable risk factors for CVD (Gu et al. ; Yokoyama et al. ), targeted interventions to control elevated BP during cold weather are particularly crucial (Xu et al. ,).1Luo Ping (2026)Effect of L‐Citrulline Intake on Blood Pressure in Cold Environments: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
L-Arginine Cardiovascular Randomized TrialOn the other hand, cold can upregulate L‐type calcium channels (Saad et al. ), induce oxidative stress (Briones and Touyz ; Martarelli et al. ), and impair endothelial NO bioavailability (Ding et al. ; Lanzinger, Breitner, et al. ), resulting in impaired vasodilatory function and increased BP.1Luo Ping (2026)Effect of L‐Citrulline Intake on Blood Pressure in Cold Environments: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
L-Arginine Cardiovascular Randomized TrialBP CI CPT CVD DBP eNOS mmHg NO PICOS PRISMA PROSPERO RCT RoB 2 SBP WMD 2024 2025 2020 2020 2023 2017 2022 2024 2022 2017 2015 2023 2019 2024 2017 2015 2018 2014 2019 2024 2015 2020 Cardiovascular disease (CVD) represents the leading cause of the global disease burden (Chong et al. ; GBD 2021 ASEAN Cardiovascular Diseases Collaborators ; Roth et al. ).1Luo Ping (2026)Effect of L‐Citrulline Intake on Blood Pressure in Cold Environments: A Systematic Review and Meta‐Analysis of Randomized Controlled Trials
L-Arginine Cardiovascular Randomized TrialThis is based on evidence from numerous randomized studies showing that treating patients with these BP values leads to benefits in the prevention and management of systemic diseases [,].2Abate Federico (2026)A Nutraceutical Approach for Hypertension: Randomized Controlled Trial of Grape Pomace Extract and L-Arginine
L-Arginine Cardiovascular Randomized TrialThe continuous relationship between blood pressure and the risk of cardiovascular events has been demonstrated at all ages and across all ethnic groups and extends from high BP levels to relatively low values [].2Abate Federico (2026)A Nutraceutical Approach for Hypertension: Randomized Controlled Trial of Grape Pomace Extract and L-Arginine
L-Arginine Cardiovascular Randomized TrialSBP becomes the dominant risk predictor with age, while diastolic elevations are more common in younger adults (<50 years) as DBP tends to change from middle age onward as a consequence of arterial stiffening [].2Abate Federico (2026)A Nutraceutical Approach for Hypertension: Randomized Controlled Trial of Grape Pomace Extract and L-Arginine
L-Arginine Cardiovascular Randomized Trial1 2 3 2 4 5 6 7 2 8 9 9 9 10 11 12 13 1 1 13 14 15 16 17 18 19 20 21 22 23 24 25 2+ 3+ &#8722; Hypertension is classified as stage 1 when the systolic pressure ranges from 130 to 139 mmHg or the diastolic pressure ranges from 80 to 89 mmHg.2Abate Federico (2026)A Nutraceutical Approach for Hypertension: Randomized Controlled Trial of Grape Pomace Extract and L-Arginine

Source documents

  1. Effect of L&#8208;Citrulline Intake on Blood Pressure in Cold Environments: A Systematic Review and Meta&#8208;Analysis of Randomized Controlled Trials
  2. A Nutraceutical Approach for Hypertension: Randomized Controlled Trial of Grape Pomace Extract and L-Arginine